Citations

Showing 10 of 108094 citations.

UBQLN4 promotes STING proteasomal degradation during cisplatin‐induced DNA damage in triple‐negative breast cancer
Yokoe, Takamichi , Kobayashi, Yuta , Murakami, Tomohiro , Bostick, Peter J., Shiloh, Yosef , Hoon, Dave S.�B. , Bustos, Matías A. , Hoon, Dave S B , Shoji, Yoshiaki

Mayo Clinic

Clinical and Translational Medicine | July 15, 2022 | Volume: 12 | Issue: 7 | Pages: No page available

10.1002/ctm2.985 | PMID 35839317 Get It

In Response
McMullen, Kaley, Harbell, Monica W. , Kraus, Molly B.

Mayo Clinic

Anesthesia & Analgesia | July 15, 2022 | Volume: 135 | Issue: 2 | Pages: e12-e13

10.1213/ane.0000000000006078 | PMID 35839505 Get It

Immune cell density differences in normal breast lobules of BRCA1/2 mutation carriers, women with benign breast disease and healthy research volunteers
Ogony, Joshua, Brahmbhatt, Rushin, Arshad, Muhammad Asad, Peña, Alvaro, Allers, Teresa, Visscher, Daniel W., Knutson, Keith L. , Hoskin, Tanya L. , Stallings‐Mann, Melody , Winham, Stacey J. , Kannan, Nagarajan , Brown, Alyssa , Sherman, Mark E. , Knutson, Keith L. , Radisky, Derek C. , Degnim, Amy C.

Mayo Clinic

No container title available | July 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1720667/v1 Get It

Abstract Purpose Breast cancer risk is elevated in pathogenic germline BRCA 1/2 mutation carriers due to compromised DNA quality control and elevated mutagenic load. We hypothesized that if immunosurveillance promotes tumor suppression, then normal breast lobules from BRCA carriers may demonstrate higher immune cell densities. Methods We assessed immune cell composition in normal breast lobules from age-matched women with progressively increased breast cancer risk, including 1) 19 women who donated normal breast tissue to the Komen Tissue Bank (KTB) at Indiana University Simon Cancer Center, 2) 15 women with biopsy-identified benign breast disease (BBD), and 3) 19 prophylactic mastectomies from women with germline mutations in BRCA1/2 genes. We performed immunohistochemical stains and analysis to quantitate immune cell densities from digital images in up to 10 representative lobules per sample. Median cell counts per mm2 were compared between groups using Wilcoxon rank-sum tests. Results Compared to BBD tissues, normal breast lobules from BRCA carriers had significantly higher densities of CD8 + cells (median 354.4 vs 200.0 cells/mm2, p = 0.01). Compared to KTB normal donor breast tissues, normal breast lobules from BRCA carriers also had significantly higher densities of CD4+ (median 116.3 vs 17.7 cells/mm2), CD8+ (354.4 vs 150.9 cells/mm2), CD11c+ (3.5% vs 0.4% pixels positive), and CD68+ (237.5 vs 57.8 cells/mm2) immune cells (each p < 0.001). Conclusions These preliminary analyses show that normal/benign breast lobules of BRCA mutation carriers contain increased immune cells compared with BBD and normal donated tissues. Future studies will be helpful to define relationships of mutations and immune responses.
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia
Muffly, Lori , Yin, Jun , Wall, Anna, Quiroz, Elisa , Advani, Anjali S. , Luger, Selina M. , Tallman, Martin S. , Litzow, Mark R. , Appelbaum, Frederick R. , Keegan, Theresa H.M. , Jacobson, Sawyer , Advani, Anjali S , Litzow, Mark R. , Erba, Harry Paul , Larson, Richard A , Muffly, Lori , Foster, Matthew C , Larson, Richard A. , Stock, Wendy

Mayo Clinic

Blood Advances | July 15, 2022 | Volume: 6 | Issue: 14 | Pages: 4085-4092

10.1182/bloodadvances.2022007197 | PMID 35838753 Get It

Abstract In this secondary analysis of Hispanic adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated on Cancer and Leukemia Group B (CALGB) 10403, we evaluated outcomes and geographic enrollment patterns relative to US population data. We used demographic, clinical, and survival data on AYAs enrolled on CALGB 10403 (N = 295, 2007-2012). Surveillance, Epidemiology, and End Results registries provided overall survival (OS) for US AYA ALL by ethnicity/race. North American Association of Cancer Registries provided AYA ALL incidence overall and proportion among Hispanics by US state. Of AYAs enrolled on CALGB 10403, 263 (89%) reported ethnicity/race: 45 (17%) Hispanic, 172 (65%) non-Hispanic White (NHW), 25 (10%) non-Hispanic Black (NHB), and 21 (8%) other. Compared with NHWs, Hispanic and NHB patients had lower household income, and Hispanic patients were more likely to harbor high-risk CRLF2 aberrations. Relative to US estimates, where Hispanic patients represented 46% of newly diagnosed AYA ALL patients and experienced inferior OS compared with NHW (P &lt; .001), Hispanic AYAs on CALGB 10403 did as well as NHW patients (3 year OS, 75% vs 74%; P = NS). Hispanic patients also had higher rates of protocol completion (P = .05). Enrollments on CALGB 10403 differed relative to the distribution of Hispanic AYA ALL in the United States: enrollment was highest in the Midwest; t and only 15% of enrollees were from states with a high proportion of Hispanic AYA ALL patients. In summary, Hispanic patients treated on CALGB 10403 did as well as NHWs and better than population estimates. Geographical misalignment between trial sites and disease epidemiology may partially explain the lower-than-expected enrollment of Hispanic AYA ALL patients.
Paralympic golf movement: the links between inclusion and treating the whole person to regain function
Luigi, Arthur Jason De , De Luigi, Arthur Jason

Mayo Clinic

Journal of Osteopathic Medicine | July 15, 2022 | Volume: 122 | Issue: 11 | Pages: 539-543

10.1515/jom-2022-0131 | PMID 35850121 Get It

Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer's disease
Alden, Eva , Twohy, Erin , Christianson, Teresa J., Kremers, Walter K. , Jack, Clifford R. , Petersen, Ronald C. , Alden, Eva C, Lundt, Emily S. , Twohy, Erin L, Stricker, Nikki H. , Jack, Clifford R , Kremers, Walter K , Machulda, Mary M. , Knopman, David S. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | July 15, 2022 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/dad2.12325 | PMID 35860792 Get It

Abstract Introduction The aim of this study was to develop a conditional normative model for Rey's Auditory Verbal Learning Test (AVLT) that accounts for practice effects. Methods In our normative sample, robust conditional norms were derived from 1001 cognitively unimpaired (CU) adults ages 50 to 89 who completed the AVLT up to eight times. Linear mixed‐effects models adjusted for baseline performance, prior test exposures, time, demographics, and interaction terms. In our preliminary validation, mean performance on conditional and typical normative scores across two to four completed follow‐up tests in preclinical Alzheimer's disease participants at baseline with positive amyloid and tau positron emission ( n = 27 CU amyloid [A]+tau[T]+) was compared to biomarker negative individuals ( n = 269 CU A–T–). Results AVLT performance using typical norms did not differ across A+T+ and A–T– groups. Conditional norms z‐scores were lower in the A+T+ relative to the A–T– group for 30‐minute recall ( P = .033) and sum of trials ( P = .030). Discussion Conditional normative methods that account for practice effects show promise for identifying longitudinal cognitive decline.
A brief human history of ankylosing spondylitis: A scoping review of pathogenesis, diagnosis, and treatment
Murphy, Sierra , Nguyen, Brandon , Brown, Nolan J. , Neal, Matthew T. , Kalani, Maziyar A. , Murphy, Sierra N, Nguyen, Brandon A., Shahrestani, Shane , Nguyen, Brandon A , Singh, Rohin , Patel, Naresh P.

Mayo Clinic

Surgical Neurology International | July 15, 2022 | Volume: 13 | Issue: No issue available | Pages: 297

10.25259/sni_294_2022 | PMID 35928330 Get It

Background: Ankylosing spondylitis (AS) is a chronic, progressive, inflammatory disease of the spine and SI joints. Diagnostic criteria and treatments have continued to evolve, necessitating a historical compendium of AS and its management. This paper aims to review the historical context underlying the discovery of AS, as well as the major diagnostic and therapeutic discoveries in the last two centuries. Methods: A scoping review of the literature pertaining to AS was performed via the Pubmed, Scopus, and Web of Science databases. Future directions of AS treatments were assessed by querying the clinicaltrials.gov website. Results: The history of AS can be traced as far back as ancient Egypt (as evidenced by the discovery of its presence in ancient Egyptian mummies) to the late 20th century, when the inherited nature of AS was linked to a genetic factor, HLA-B27. Each discovery made throughout the years led to further investigations into the pathophysiology, diagnosis, and treatment of AS. The criteria to differentiate AS from rheumatoid arthritis were first reported in 1893. Since then, diagnostic criteria for AS have undergone a series of changes before the present-day diagnostic criteria for AS were ultimately determined in 2009 by the Assessment of Spondyloarthritis International Society. Conclusion: As the pathophysiology of AS is better understood, healthcare providers are able to diagnose and treat the condition more effectively. In particular, earlier diagnosis and multiple treatment options have facilitated efficient and more effective treatment.
Microsurgical Resection of Optic Chiasm Cavernous Malformations: 2-Dimensional Operative Video
Patra, Devi Prasad, Turcotte, Evelyn L. , Turkmani, Ali , Krishna, Chandan , Bendok, Bernard R. , Patra, Devi P. , Turkmani, Ali H, Bendok, Bernard R

Mayo Clinic

Operative Neurosurgery | July 15, 2022 | Volume: 23 | Issue: 2 | Pages: e129-e129

10.1227/ons.0000000000000268 | PMID 35838473 Get It

Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia
Yu, Ming , Moinova, Helen , Willbanks, Amber, Cannon, Victoria K., Wang, Ting , Carter, Kelly , Kaz, Andrew M. , Reddi, Deepti , Inadomi, John M. , Luebeck, E. Georg , Iyer, Prasad G. , Wang, Jean S. , Shaheen, Nicholas J. , Thota, Prashanti N., Willis, Joseph , LaFramboise, Thomas , Chak, Amitabh , Markowitz, Sanford D. , Moinova, Helen R , Inadomi, John , Luebeck, Georg , Shaheen, Nicholas J , Chak, Amitabh , Grady, William M , Willis, Joseph E , Carter, Kelly , Cannon, Victoria K., Reddi, Deepti , Canto, Marcia Irene , Grady, William M.

Mayo Clinic

Clinical Cancer Research | July 15, 2022 | Volume: 28 | Issue: 17 | Pages: 3761-3769

10.1158/1078-0432.ccr-22-0445 | PMID 35705525 Get It

Abstract Purpose: Current endoscopy-based screening and surveillance programs have not been proven effective at decreasing esophageal adenocarcinoma (EAC) mortality, creating an unmet need for effective molecular tests for early detection of this highly lethal cancer. We conducted a genome-wide methylation screen to identify novel methylation markers that distinguish EAC and high-grade dysplasia (HGD) from normal squamous epithelium (SQ) or nondysplastic Barrett's esophagus (NDBE). Experimental Design: DNA methylation profiling of samples from SQ, NDBE, HGD, and EAC was performed using HM450 methylation arrays (Illumina) and reduced-representation bisulfate sequencing. Ultrasensitive methylation-specific droplet digital PCR and next-generation sequencing (NGS)-based bisulfite-sequencing assays were developed to detect the methylation level of candidate CpGs in independent esophageal biopsy and endoscopic brushing samples. Results: Five candidate methylation markers were significantly hypermethylated in HGD/EAC samples compared with SQ or NDBE (P &lt; 0.01) in both esophageal biopsy and endoscopic brushing samples. In an independent set of brushing samples used to construct biomarker panels, a four-marker panel (model 1) demonstrated sensitivity of 85.0% and 90.8% for HGD and EACs respectively, with 84.2% and 97.9% specificity for NDBE and SQ respectively. In a validation set of brushing samples, the panel achieved sensitivity of 80% and 82.5% for HGD and EAC respectively, at specificity of 67.6% and 96.3% for NDBE and SQ samples. Conclusions: A novel DNA methylation marker panel differentiates HGD/EAC from SQ/NDBE. DNA-methylation–based molecular assays hold promise for the detection of HGD/EAC using esophageal brushing samples.